Wei Zhuang

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 16

Top Topics

Interstitial Lung Disease

Tyrosine Kinase

Systemic Sclerosis

Top Venues

International journal of clinical pharmacy

Clinical cancer research : an official journal of the American Association for Cancer Research

BMC pharmacology & toxicology

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiao-Xu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xue-Ding Wang, Li Zhang
Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiao-Xu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xue-Ding Wang, Li Zhang
Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Wanlong Lin, Jiabing Xu, Yufang Liao, Xiuxian Lin, Jianhui Yang, Wei Zhuang
Author Correction: Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system. International journal of clinical pharmacy (2024)
Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiao-Xu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xue-Ding Wang, Li Zhang
Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
Lisha Wu, Hongyan Huang, Yimin Zhang, Wei Zhuang, Xiaorong Lin
Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system. Expert opinion on drug safety (2024)
Wanlong Lin, Yanbin Zeng, Lizhu Weng, Jianhui Yang, Wei Zhuang
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study. BMC pharmacology & toxicology 25 (1) (2024)
Wanlong Lin, Yanbin Zeng, Lizhu Weng, Jianhui Yang, Wei Zhuang
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study. BMC pharmacology & toxicology 25 (1) (2024)
Wanlong Lin, Yanbin Zeng, Lizhu Weng, Jianhui Yang, Wei Zhuang
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study. BMC pharmacology & toxicology 25 (1) (2024)
Jing Huang, Anping Su, Jing Yang, Wei Zhuang, Zhihui Li
Post-marketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment. The Journal of clinical endocrinology and metabolism (2024)
Jianhui Yang, Can Cai, Xiuming Pan, Weida Chen, Wei Zhuang, Wanlong Lin, Yao Chen
A 10-year retrospective study of antibacterial-induced thrombocytopenia in a women and children hospital using China Hospital Pharmacovigilance System and Visual Basic for Applications. British journal of clinical pharmacology (2024)
Wei Zhuang, Jiabing Xu, Ye Wu, Jianhui Yang, Xiuxian Lin, Yufang Liao, Jun Wan, Lizhu Weng, Wanlong Lin
Post-Marketing Safety Concerns with Nirmatrelvir: A Disproportionality Analysis of Spontaneous Reports Submitted to FDA Adverse Event Reporting System. British journal of clinical pharmacology (2023)
Wanlong Lin, Jiabing Xu, Yufang Liao, Xiuxian Lin, Jianhui Yang, Wei Zhuang
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system. International journal of clinical pharmacy (2023)
Wanlong Lin, Jiabing Xu, Yufang Liao, Xiuxian Lin, Jianhui Yang, Wei Zhuang
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system. International journal of clinical pharmacy 46 (3) (2023)
Wanlong Lin, Jiabing Xu, Yufang Liao, Xiuxian Lin, Jianhui Yang, Wei Zhuang
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system. International journal of clinical pharmacy (2023)
Wanlong Lin, Jiabing Xu, Yufang Liao, Xiuxian Lin, Jianhui Yang, Wei Zhuang
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system. International journal of clinical pharmacy (2023)
Shaoxing Guan, Xi Chen, Youhao Chen, Wen Xie, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Wei Zhuang, Shu Liu, Min Huang, Xueding Wang, Li Zhang
FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (17) (2022)